Table 1.
Participant Demographics (Safety Population)
| Placebo (N = 59) | Atogepant 300 mg (N = 60) | Moxifloxacin 400 mg (N = 59) | All Participants (N = 60) | |
|---|---|---|---|---|
| Age, y, mean (SD) [range] | 33.5 (7.3) [18–44] | 33.6 (7.3) [18–44] | 33.5 (7.3) [18–44] | 33.6 (7.3) [18–44] |
| Sex, n (%) | ||||
| Female | 31 (52.5) | 32 (53.3) | 31 (52.5) | 32 (53.3) |
| Male | 28 (47.5) | 28 (46.7) | 28 (47.5) | 28 (46.7) |
| Race, n (%) | ||||
| White | 34 (57.6) | 34 (56.7) | 34 (57.6) | 34 (56.7) |
| Black/African American | 22 (37.3) | 23 (38.3) | 22 (37.3) | 23 (38.3) |
| Asian | 2 (3.4) | 2 (3.3) | 2 (3.4) | 2 (3.3) |
| Native Hawaiian or Other Pacific Islander | 1 (1.7) | 1 (1.7) | 1 (1.7) | 1 (1.7) |
| Ethnicity, n (%) | ||||
| Hispanic | 22 (37.3) | 22 (36.7) | 22 (37.3) | 22 (36.7) |
| Non‐Hispanic | 37 (62.7) | 38 (63.3) | 37 (62.7) | 38 (63.3) |
| Weight, kg, mean (SD) | 71.8 (12.2) | 71.9 (12.2) | 71.8 (12.2) | 71.9 (12.2) |
| Height, cm, mean (SD) | 167.0 (8.7) | 167.0 (8.7) | 167.0 (8.7) | 167.0 (8.7) |
| BMI, kg/m2, mean (SD) | 25.6 (2.9) | 25.7 (2.9) | 25.6 (2.9) | 25.7 (2.9) |
BMI, body mass index; SD, standard deviation.